



PATENT
Attorney Docket No: UM-07269

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gary D. Glick
Serial No.: 09/767,283
Filed: 1/22/2001
Entitled: **Therapeutic Application of Pro-Apoptotic Benzodiazepines**

Group No.: 1618
Examiner: Kim, Vickie, Y.

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)	
I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Date: <u>4/24/06</u>	By: <u>Jasmine M. Stansberry</u> Jasmine M. Stansberry

Sir or Madam:

Enclosed please find a **Supplemental Information Disclosure Statement** and Form PTO-1449, in the above-identified application, for filing in the U.S. Patent Office.

Applicants believe no fee is required. The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: 4-24-06

Robert A. Goetz
Robert A. Goetz
Registration No. 55,210

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 305
San Francisco, California 94105
608/218-6900



PATENT

⁴¹ Attorney Docket No. UM-07269

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gary D. Glick

Serial No.: 09/767,283

Filed: 1/22/2001

Entitled: **Therapeutic Application of Pro-Apoptotic Benzodiazepines**

Group No.: 1618

Examiner: Kim, Vickie Y

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)	
I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Date: <u>4/24/06</u>	By: <u>Jasmine M. Stansberry</u> Jasmine M. Stansberry

Sir or Madam:

The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- US Patent 5,697,967, Issued December 16, 1997, Thomas Q. Dihn, et al.
- US Patent 5,599,352, Issued February 04, 1997, Thomas Q. Dihn, et al.
- US Patent 5,591,227, Issued January 07, 1997, Thomas Q. Dihn, et al.
- WO 91/12779, Issued September 05, 1991, Wolff, R.G., et al.
- WO 90/13332, Issued November 15, 1990, Siegel, R.J., et al.
- Dichek, David A., Laboratory Investigation, Vol. 80, No. 5, pp. 1347-1353, November 1989.
- Don, Anthony, Cancer Cell, Vol. 3, PP.497-509, May 2003.
- Atwal, K.S., et al., J. Med. Chem., Vol. 47, pp. 1081-1084, January 2004.



PATENT

• Attorney Docket No. UM-07269

- Atwal, K.S., et al., Bioorganic & Medicinal Chemistry Letters, Vol. 14, pp. 1027-1030, 2004
- Hamann, L.G., et al., Bioorganic & Medicinal Chemistry Letters, Vol. 14, pp. 1031-1034, 2004


Applicants wish to bring to the examiners attention that we are not providing copies of US Patents as instructed under 37 CFR 1.98(a)(2).

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: 4-24-06

Robert A. Goetz
Registration No. 55,210

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608/218-6900



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet

1

of

12

Complete if Known

Application Number	09/767,283
--------------------	------------

Filing Date	1/22/2001
-------------	-----------

First Named Inventor	Gary D. Glick
----------------------	---------------

Art Unit	1618
----------	------

Examiner Name	Kim, Vickie Y.
---------------	----------------

Attorney Docket Number	UM-07269
------------------------	----------

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ ~Number ⁴ ~Kind Code ⁵ (if known)				
	4	WO 91/12779	09/05/1991	Wolff, et al.	whole document	
	5	WO 90/13332	11/15/1990	Siegel, et al.	whole document	

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/767,283		
		Filing Date	1/22/2001		
		First Named Inventor	Gary D. Glick		
		Art Unit	1618		
		Examiner Name	Kim, Vickie Y.		
Sheet	2	of	2	Attorney Docket Number	UM-07269

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	6	Dichek, D.A., "Seeding of Intravascular Stents With Genetically Engineered Endothelial Cells" Laboratory Investigation, Vol. 80, No. 5, pp. 1347-1353, November, 1989	
	7	Don, A.S., et al., "A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells" Cancer Cell, Vol. 3, PP.4	
	8	Atwal, K.S., et al., "Small Molecule Mitochondrial F1F0 ATPase Hydrolase Inhibitors as Cardioprotective Agents", J. Med. Chem., 47, pp.1081-1084(2004)	
	9	Atwal, K.S. et al., "N-[1-Aryl-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F1F0 ATP hydrolase" Bioorganic & Medicinal Chem. L	
	10	Hamann, L.G., et al., "Benzodiazepine-based selective inhibitors of mitochondrial F1F0 ATP hydrolase", Bioorganic & Medicinal Chemistry Ltrs., Vol. 14, pp. 1031-1034 (2004)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.